Jump to main content
Jump to site search

Issue 43, 2016
Previous Article Next Article

Design, synthesis, and biological evaluation of CXCR4 ligands

Author affiliations

Abstract

A combination of the CXCR4 inverse agonist T140 with N-terminal CXCL12 oligopeptides has produced the first nanomolar synthetic CXCR4 agonists. In these agonists, the inverse agonistic portion provides affinity whereas the N-terminal CXCL12 sequence induces receptor activation. Several CXCR4 crystal structures exist with either CVX15, an inverse agonist closely related to T140 and IT1t, a small molecule; we therefore attempted to produce another CXCL12 oligopeptide combination with IT1t. For this purpose, a primary amino group was introduced by total synthesis into one of the methyl groups of IT1t, serving as an anchoring point for the oligopeptide graft. The introduction of the oligopeptides on this analog however yielded antagonists, one compound displaying high affinity. On the other hand, the amino-substituted analogue itself proved to be an inverse agonist with a binding affinity of 2.6 nM compared to 11.5 nM for IT1t. This IT1t-like analog is hitherto one of the most potent non-peptidic CXCR4 inverse agonists reported.

Graphical abstract: Design, synthesis, and biological evaluation of CXCR4 ligands

Back to tab navigation

Supplementary files

Publication details

The article was received on 12 Jul 2016, accepted on 04 Oct 2016 and first published on 04 Oct 2016


Article type: Paper
DOI: 10.1039/C6OB01484D
Citation: Org. Biomol. Chem., 2016,14, 10298-10311
  •   Request permissions

    Design, synthesis, and biological evaluation of CXCR4 ligands

    C. E. Mona, É. Besserer-Offroy, J. Cabana, R. Leduc, P. Lavigne, N. Heveker, É. Marsault and E. Escher, Org. Biomol. Chem., 2016, 14, 10298
    DOI: 10.1039/C6OB01484D

Search articles by author

Spotlight

Advertisements